TORONTO, May 2, 2019 /CNW/ - Bill Radvak, Executive Chairman, NervGen Pharma Corp. (NGEN), joined Tim Babcock, Managing Director, Capital Formation, TSX Venture Exchange, to open the market. NervGen is a regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. NervGen Pharma Corp. commenced trading on TSX Venture Exchange on March 13, 2019.

NervGen Pharma Corp. Opens the Market (CNW Group/TMX Group Limited)

SOURCE TMX Group Limited

Copyright 2019 Canada NewsWire

Nervgen Pharma (TSXV:NGEN)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Nervgen Pharma Charts.
Nervgen Pharma (TSXV:NGEN)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Nervgen Pharma Charts.